2023
Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
Castro D, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 453-453. DOI: 10.1200/jco.2023.41.6_suppl.453.Peer-Reviewed Original ResearchHIV positivityHCV positivityEligibility criteriaCancer trialsExclusion criteriaConcurrent malignancyBrain metastasesCombination therapyExact testClass of therapyTrial eligibility criteriaReal-world populationFisher's exact testRestrictive eligibility criteriaSpecific study populationMultiple cancer typesChemotherapy trialsReal-world practiceInvestigational treatmentStudy populationRadiation therapyClinical OncologyPrognostic toolTherapySignificant association
2021
Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations.
Meza L, Filippov A, Naim S, Dizman N, Chehrazi-Raffle A, Philip E, Maholtra J, Muddasani R, Chawla N, Wong C, Salgia S, Karimi M, Trent J, Byron S, Chaudhry A, Pal S. Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations. Journal Of Clinical Oncology 2021, 39: 282-282. DOI: 10.1200/jco.2021.39.6_suppl.282.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMetastatic sitesRenal cell carcinomaBAP1 mutationsWhole-exome sequencingRadiomic featuresCell carcinomaNon-invasive methodPrimary tumorTERT mutationsClear cell histologyPoor clinical outcomeRoutine clinical careMajority of ptsCell histologyClinical outcomesPrimary lesionClinical careMutation statusMutational statusSignificant associationCT imagingExome sequencingRadiomics analysisCancer Imaging Archive